Pharmacokinetic and safety study of subcutaneously administered weekly ING-1, a human engineered™ monoclonal antibody targeting human EpCAM, in patients with advanced solid tumors

S. Goel, R. J. Bauer, K. Desai, A. Bulgaru, T. Iqbal, B. K. Strachan, G. Kim, A. Kaubisch, G. F. Vanhove, G. Goldberg, S. Mani

Research output: Contribution to journalArticle

18 Scopus citations


Background: ING-1 is a high-affinity, human engineered™ monoclonal antibody that recognizes a 40 kilodalton epithelial cell adhesion molecule (EpCAM) glycoprotein that is expressed in high levels on most adenocarcinomas and is an attractive target for immunotherapy. Methods:ING-1 was administered subcutaneously weekly at doses between 0.1 and 2 mg/kg/week. Pharmacokinetic samples were drawn during weeks 1 and 6. Results: Fourteen patients with advanced refractory cancer received a median of 6 (range 1-9) doses of ING-1. At 1 mg/kg, a 62-year-old man with colon cancer developed reversible grade 3 pancreatitis after the third dose. His plasma ING-1 levels were similar to the other two patients dosed at 1 mg/kg. Two patients dosed at 0.6 mg/kg experienced stable disease at 6 weeks. Peak drug levels increased with dose and time, suggesting drug accumulation with repeated dosing. Low human anti-human antibody response was noted in three of the 13 patients assessed and was directed towards the variable region of ING-1. Conclusions: Weekly ING-1 administered subcutaneously was well tolerated at 0.6 mg/kg/week and further experience at this dose is warranted to demonstrate safety. The risk of pancreatitis and the marginal anti-tumor effect may preclude further monotherapy studies; however, combination studies with chemotherapy are warranted.

Original languageEnglish (US)
Pages (from-to)1704-1707
Number of pages4
JournalAnnals of Oncology
Issue number10
StatePublished - Oct 1 2007



  • Cancer
  • EpCAM
  • ING-1
  • Pharmacokinetics
  • Phase I

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this